The immune-suppressive T-cell markers CD25, cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and Foxp3 were upregulated, whereas expression of the immune activation marker CD28 was downregulated in these cells. We also showed that levels of Foxp3 in CD8 + T cells were positively associated with tumor stage in OC patients, suggesting that CD8 + Foxp3 + Treg cells contribute to the progression of OC. This highlights the role of CD8 + Foxp3 + Treg cells as predictors of clinical outcome in OC patients. Then we determined whether the tumor microenvironment had the ability to convert CD8 + effector T cells into suppressor cells. We observed phenotypic similarities between CD8 + Tcells in transwell co-culture system and CD8 + T cells obtained from OC tumor tissues, including upregulated Foxp3 and CTLA-4 and downregulated CD28 expression levels. 6 The in vitroinduced CD8
+ Treg cells also secreted higher concentrations of transforming growth factor β1 (TGF-β1), interferon (IFN)-γ, tumor necrosis factor (TNF)-α,and interleukin (IL)−2. The Foxp3 + CTLA-4 + and TGF-β1 + phenotype indicated that the induced CD8 + Treg cells were functionally activated, which was confirmed by their ability to suppress CD4 + T-cell proliferation partially by TGF-β1and IFN-γ. These data imply that CD8
+ Treg cells accumulated in OC tissue in vivo and inducible in vitro may dampen antitumor immunity and contribute to tumor immune evasion.
TGF-β1 also has a crucial role in the development of Treg cells, 7 and CD4 + CD25 − T cells deficient in the TGF-β signaling pathway cannot be converted into Foxp3
+ iTreg cells. 8 We showed that OC SKOV3 cells induced CD8
+ Treg cells by secreting TGF-β1and that OC patients expressed high levels of TGF-β1, correspondingly, increased TGFβ1 secretion was demonstrated in supernatant from the co-culture system of CD8 + T cells and SKOV3. Additionally, TGF-β1 levels were positively correlated with the percentage of CD8 + Treg cells in OC. 9 Consistent with previous reports, 10 we also confirmed that high expression TGF-β1 at least partially contributed to the suppressive function of in vitroinduced CD8
+ Treg cells. Compared with CD8 + T cells cultured alone, CD8 + T cells cocultured with SKOV3 cells exhibited marked activation of p38 mitogen-activated protein kinase (MAPK), which could be inhibited by a TGF-β1-neutralizing antibody. Moreover, the TGF-β1-triggered conversion to CD8 + Treg cells in the tumor microenvironment CD8 + Treg cells in vitro was dosedependently blocked by the p38-specific inhibitor SB203580, indicating that the induction of CD8 + Treg cells depended in part on TGF-β1-activated p38 MAPK signaling. These findings indicate that TGF-β1 is a potential target in the treatment of OC.
We further investigated the molecular signatures that contributed to the induction of CD8 + Treg cells by comparing the expressed gene profiles when CD8 + T cells were cultured with or without SKOV3 cells.
11 DNA microarray data showed that 73% of previously reported CD8 + Treg cell molecular markers were significantly upregulated during co-culture with SKOV3 cells. Among them, ITGAX, also known as CD11c, was particularly noteworthy. This observation is consistent with previous reports that CD11c high CD8 + Treg cells possess potent cytotoxicity to target cells via the Fas/Fas ligand pathway and that this subset of CD8 + Treg cells can inhibit the CD4 + T-cell-mediated immune response by killing the activated CD4 + Tcells. 12 Interestingly, we found that the expression of glycolysis genes in CD8 + Tcells was decreased during co-culture with SKOV3 cells, while their expression was negatively correlated with Foxp3 expression in CD8 + Treg cells. This indicated that the glycolysis pathway may contribute to the differentiation and generation of CD8 + Treg cells. Further efforts areneededtofully reveal theunderlying mechanism of CD8 + Treg cells' differentiation and activation in an ovarian microenvironment.
Taken together, these findings suggest that CD8 + Treg cells accumulate in human OC tissues and display an activated phenotype with suppressive functions. Although CD8 + Treg cells represent only a small fraction of CD8 + T cells in vivo, targeting CD8 + Treg cells may potentiate the antitumor immunity and rebalance the OC microenvironment. We are attempting to confirm the clinical relevance of this hypothesis. + Treg cells may play a role in promoting imbalance of the immune system in tumor growth. These immune-tolerance mechanisms may also be exploited by cancer cells to achieve immune escape, which becomes more pronounced with tumor formation, progression and metastasis. CTLA-4, cytotoxic T-lymphocyte associated protein 4; HIF1α, hypoxia-inducible factor 1α; IL, interleukin; MAPK, mitogen-activated protein kinase; mTORC1, mammalian target of rapamycin complex 1; OC, ovarian cancer; TGF-β, transforming growth factor β;TNF-α, tumor necrosis factor α;Treg, regulatory T Immune regulation by CD8 + Treg cells:. . . S Zhang et al.
